The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs. Reporting directly to the EVP, Chief Legal and Business Officer, this attorney will be the only other corporate lawyer at the company and will work on a broad range of legal matters including contracts, SEC reporting, corporate governance, compliance, and other business-related legal needs.